The paradigm change from reactive medical services to 3PM in ischemic stroke: a holistic approach utilising tear fluid multi-omics, mitochondria as a vital biosensor and AI-based multi-professional data interpretation.

"Declarations Ethics approvalAll investigations made on human participants were conducted according to the guidelines of the Declaration of Helsinki. Ethical approval has been provided by responsible bodies in Germany (Ethical Commission of Medical Faculty, University of Bonn, protocol number 505/20 dated on November 11th, 2020), Switzerland (Commission cantonale d’éthique de la recherche de Genève, CCER, University of Geneva, protocol code 2020–02196, 19 November 2020) and Czech Republic Czech Republic (University Hospital Pilsen and Faculty of Medicine in Plzen, Charles University, Prague, protocol number FN/1252/01 dated on July 2nd 2020). Conflicts of InterestThe authors declare no conflict of interest. Prof. Dr. Olga Golubnitschaja is an editor of the EPMA J., and recused herself from all decisions about the paper. She is a shareholder of 3PMedicon. Dr. Jiri Polivka Jr. is a shareholder of 3PMedicon. Conflicts of Interest The authors declare no conflict of interest. Prof. Dr. Olga Golubnitschaja is an editor of the EPMA J., and recused herself from all decisions about the paper. She is a shareholder of 3PMedicon. Dr. Jiri Polivka Jr. is a shareholder of 3PMedicon."

"Funding Open Access funding enabled and organized by Projekt DEAL. The cumulative research paper was supported by the following: • The European Association for Predictive, Preventive and Personalised Medicine, EPMA, Brussels • The Cooperation Programme, research area MED/DIAG, Charles University and by a grant from the Ministry of Health of the Czech Republic - Conceptual Development of Research Organization (University Hospital Pilsen—FNPL, 00669806) • The LHW Foundation, Liechtenstein."